For all enrolled patients with breast carcinoma, the results indicated that the DFS and OS time in patients with low SII were significantly longer than that in those patients with high SII in HER2‐enriched subtype (χ2 = 4.448, P = .035 and χ2 = 4.371, P = .037, respectively; Figure 3G, H). This evidence concerns the gene ERBB2 and breast carcinoma.